<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39412285</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Rapid detection of SARS-CoV-2 variants by molecular-clamping technology-based RT-qPCR.</ArticleTitle><Pagination><StartPage>e0424823</StartPage><MedlinePgn>e0424823</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.04248-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">Given the challenges that SARS-CoV-2 variants have caused in terms of rapid spread and reduced vaccine efficacy, a rapid and cost-effective assay that can detect new and emerging variants is greatly needed worldwide. We have successfully applied the xenonucleic acid-based molecular-clamping technology to develop a multiplex reverse-transcription quantitative real-time PCR assay for SARS-CoV-2 multivariant detection. The assay was used to test 649 nasopharyngeal swab samples that were collected for clinical diagnosis or surveillance. The assay was able to correctly identify all 36 Delta variant samples as it accurately detected the D614G, T478K, and L452R mutations. In addition, the assay was able to correctly identify all 34 Omicron samples by detecting the K417N, T478K, N501Y, and D614G mutations. This technique reliably detects a variety of variants and has an analytical sensitivity of 100 copies/mL. In conclusion, this novel assay can serve as a rapid and cost-effective tool to facilitate large-scale detection of SARS-CoV-2 variants.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">We have developed a multiplex reverse-transcription quantitative real-time PCR (RT-qPCR) testing platform for the rapid detection of SARS-CoV-2 variants using the xenonucleic acid (XNA)-based molecular-clamping technology. The XNA-based RT-qPCR assay can achieve high sensitivity with a limit of detection of about 100 copies/mL for variant detection which is much better than the next-generation sequencing (NGS) assay. Its turnaround time is about 4 hours with lower cost and a lot of Clinical Laboratory Improvement Amendments (CLIA) labs own the instrument and meet skillset requirements. This assay provides a rapid, reliable, and cost-effective testing platform for rapid detection and monitoring of known and emerging SARS-CoV-2 variants. This testing platform can be adopted by laboratories that perform routine SARS-CoV-2 PCR testing, providing a rapid and cost-effective method in lieu of NGS-based assays, for detecting, differentiating, and monitoring SARS-CoV-2 variants. This assay is easily scalable to any new variant(s) should it emerge.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shen</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3517-8971</Identifier><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fu</LastName><ForeName>Andrew Y</ForeName><Initials>AY</Initials><Identifier Source="ORCID">0000-0002-1507-0787</Identifier><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jamba</LastName><ForeName>Maidar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cataldi</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathakamuri</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuebler</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohall</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krohn</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kissinger</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neves</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archibeque</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Franciscan University of Steubenville, Steubenville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Aiguo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chuanyi M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, University of California San Francisco and San Francisco VA Health Care System, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sha</LastName><ForeName>Michael Y</ForeName><Initials>MY</Initials><Identifier Source="ORCID">0000-0002-4552-6079</Identifier><AffiliationInfo><Affiliation>DiaCarta Inc., Pleasanton, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARA-CoV-2 variant detection</Keyword><Keyword MajorTopicYN="N">XNA</Keyword><Keyword MajorTopicYN="N">molecular-clamping technology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39412285</ArticleId><ArticleId IdType="doi">10.1128/spectrum.04248-23</ArticleId></ArticleIdList></PubmedData></PubmedArticle>